

# Nizoral<sup>®</sup>

ketoconazole

**The first  
oral anti-fungal  
effective against  
all pathogenic  
fungi**

dosage:

vaginal candidosis:	all other superficial and systemic fungal infections:
2 tablets once daily (with food) for 5 days	1 tablet daily (with food) until complete symptomatic and mycological cure is obtained

#### **PRESCRIBING INFORMATION**

**Presentation:** white, flat, half scored uncoated tablets marked "Janssen" on one side and 1/200 on the reverse. Each tablet contains 200 mg ketoconazole. **Uses:** Nizoral is an orally active antimycotic for the treatment in adults, of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and G.I. tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children: systemic mycoses and severe local infections where previous topical treatment has failed. **Side-effects, precautions, contra-indications:** contra-indicated in pregnancy. For maximal absorption Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H<sub>2</sub> blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole, these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped.

Not all indications are as yet approved in all countries.

Janssen Pharmaceutica  
B-2340 Beerse, Belgium



# HISTORY OF THE BRITISH MEDICAL ASSOCIATION

Volume II 1932-1981

by

ELSTON GREY-TURNER  
CBE, MC, TD, MD, MRCS, LRCP  
(Secretary, BMA, 1976-79)

and

F M SUTHERLAND  
MA, FLA  
(Librarian, BMA, 1961-81)

A companion volume to the history of the BMA's first hundred years published in 1932, *The History of the BMA Volume II* covers the next 50 years. The authors, Dr E Grey-Turner, former secretary of the BMA, and Mr F Sutherland, former librarian of the BMA, describe the change in the BMA's role overseas, the baffling new ethical problems, and the expansion of the BMA's publishing activities. Their book is packed with fascinating information. Why did the BMA threaten the *Sunday Pictorial* at the beginning of the second world war? What did the presidents of the royal colleges say in their famous letter to Aneurin Bevan? What was the biggest award ever made to doctors by a Review Body? All these questions, and many more, are answered in this book.

Price: Hardback — £12.25 (US\$30.60)    Paperback — £10.00 (US\$25.00)

Volumes I & II in slip case — £19.25 (US\$48.10)

**Reduced price for BMA members only**

Hardback — £11.00 (US\$27.50)    Paperback — £9.00 (US\$22.50)

Volumes I & II in slip case — £17.25 (US\$43.15)

Order your copy now from: The Publisher, British Medical Journal,  
BMA House, Tavistock Square, London WC1H 9JR



## Septtrin Assurance

### Prescribing Information

**Indications** Sensitive bacterial infections of the lower respiratory, urinary and genital tracts, sinusitis, otitis media, skin infections, septicaemia, typhoid and paratyphoid fevers, and other infections caused by sensitive organisms.

**Dosage** Septtrin Forte Tablets. Adults and children over 12 years: 1 forte tablet twice daily. Maximum dosage for particularly severe infections 1½ forte tablets twice daily. In acute infections Septtrin should be given for a minimum of five days or until the patient has been symptom-free for two days.

**Contra-indications** Septtrin is contra-indicated in

patients with marked liver parenchymal damage, blood dyscrasias or severe renal insufficiency.

Septtrin should not be given to patients hypersensitive to sulphonamides, trimethoprim or co-trimoxazole; should not be given during pregnancy or to neonates.

**Precautions** In renal impairment a reduced dosage is indicated and an adequate urinary output should be maintained. Regular blood counts are necessary whenever long-term therapy is used. Caution is advised in patients with folate deficiency. Care should be taken when giving Septtrin to patients receiving oral anticoagulants of the coumarin group, pyrimethamine or sulphonylureas.

**Adverse Reactions** Occasionally, nausea, vomiting, glossitis and skin rashes may occur with normal doses and, very rarely, haematological reactions.

**Presentation** Septtrin Forte Tablets each contain 160 mg Trimethoprim BP and 800 mg Sulphamethoxazole BP. PL3/0121.

## Septtrin\* Forte 1b.d. co-trimoxazole

Further information is available on request.  
Wellcome Medical Division  
The Wellcome Foundation Ltd., Crewe, Cheshire




\*Trade Mark

---

# CALCISORB

## sodium cellulose phosphate

---



**F**or the treatment of absorptive hypercalciuria associated with recurrent formation of renal calculi

**Prescribing information. Composition:** Each 5g sachet contains 4.7g sodium cellulose phosphate. **Indications:** Calcisorb is used to diminish calcium absorption from the diet: 1) in the treatment of hypercalciuria and recurrent formation of renal stones 2) in osteopetrosis 3) as a basis of a test for calcium absorption. Other possible uses are: 1) treatment of idiopathic hypercalcaemia of infancy 2) treatment of hypercalcaemic sarcoidosis 3) treatment of vitamin D intoxication. **Dosage and administration:** Adults: 15g daily, divided as three 5g doses with meals. Children: 10g daily, divided as three doses with meals. The required dose should be dispersed in water and taken orally. Alternatively the powder may be sprinkled onto food. **Side-effects:** Side-effects are rare. Isolated cases of diarrhoea have been reported. One patient with mild renal disease, developed a moderate magnesium deficiency. This was readily corrected by halving the dose. **Caution:** No signs of calcium deficiency have been reported during the continuous use of cellulose phosphate for up to 11 years. This theoretical hazard is particularly relevant to pregnancy, but in view of the absence of data on the effect of cellulose phosphate on calcium levels in pregnant women it is recommended that treatment is discontinued during pregnancy and lactation. Likewise growing children should be prescribed Calcisorb only at the discretion of a senior physician and under his direct supervision. **Contra-indications:** Renal failure. Congestive heart failure and other conditions in which a low sodium intake is essential. **Further Information:** Calcisorb should be used in conjunction with a low calcium diet in which dairy products in particular are severely restricted. **Basic NHS price:** Packs of 100 x 5g sachets: £18.22. **Product licence number:** 68/5900. *Calcisorb; Riker; 3M:* trade marks. Further information is available on request.

# In hypertension

# TENORMIN

Atenolol 100mg

## The only beta-blocker to put it all together in one.

Full 24 hour control

One tablet daily

Wide patient  
spectrum

Few CNS  
side-effects

Hydrophilic

Possible  
advantages  
in smokers

Cardioselective

Cardioprotective

## Tenormin fits the profile of the ideal beta-blocker for hypertension.

# TENORMIN

A unique combination of hydrophilicity  
and cardioselectivity

**Prescribing Notes:**

**Dosage:** One tablet daily. **Contraindications:** Heart block. Co-administration with verapamil. **Precautions:** Untreated cardiac failure, bradycardia, renal failure, anaesthesia and pregnancy. **Side Effects:** Coldness of extremities and muscular fatigue. Sleep disturbance rarely seen. Rashes and dry eyes have been reported with beta blockers - consider discontinuance if they occur. Cessation of therapy with beta blockers should be gradual. **Pack size and Basic NHS cost:** 'Tenormin' 28's £7.27.  
**Product Licence Number:** 'Tenormin' 0029/0122.

Full prescribing information is available on request to the company



**Stuart Pharmaceuticals Limited**  
Carr House Carrs Road  
Cheadle Cheshire SK8 2EG  
Tenormin is a trade mark for atenolol.

